Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
← catalyst calendarNCT06825702 · readout ≤ 103 d
Sponsored by Kiora Pharmaceuticals, Inc. (industry) · KPRX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
28estimated
Sites
6
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-01 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Macular Edema
Intervention
- Drug: KIO-104
Primary outcome
what the primary-completion date above is the date OFSafety and Tolerability
measured 23months
Publications
- PMID 36325389 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · KPRX's whole pipeline · Catalyst calendar · Every registered study · What changed